Trial results

A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes

NCT06559722 on ClinicalTrials.gov · last registry update 2024-08-19

510 participants. The sponsor logged completion for October 2025. Primary outcome, as filed: Change from baseline in HbA1c after 26 weeks of treatment. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status

UNKNOWN

Phase

P3

Drug

liraglutide

Victoza, Xultophy, Saxenda

Sponsor

Tonghua Dongbao Pharmaceutical Co.,Ltd

Sponsor type

Industry

Enrollment

510

Started

2024-08

Primary completion

2025-10 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Change from baseline in HbA1c after 26 weeks of treatment

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.